Security key
29384C108
Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA)
CUSIP: 29384C108
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 38,346,880
- Total 13F shares
- 25,477,255
- Share change
- +655,644
- Total reported value
- $321,439,067
- Put/Call ratio
- 0%
- Price per share
- $12.62
- Number of holders
- 118
- Value change
- +$9,380,321
- Number of buys
- 61
- Number of sells
- 45
Report period
Q1 2026
Institutions
118
Top holders
10
TRDA full security history
Previous quarter: Q4 2025
Entrada Therapeutics, Inc. SEC filings
Entrada Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29384C108
Recent filing periods:
Top shareholders of TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| 5AM Ventures V, L.P. |
3/4/5
13D/G
|
10%+ Owner · Kush Parmar |
11%
from 13D/G
|
4,056,379
|
$32,831,654 | -$2,829,187 | 14 Nov 2025 | |
| ROCHE FINANCE LTD |
13D/G
|
— |
6.9%
|
2,569,115
|
$23,019,270 | $0 | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.3%
from 13D/G
|
2,147,260
|
$22,073,833 | — | 31 Dec 2025 | |
| TCG Crossover GP I, LLC |
13D/G
|
— |
5%
|
1,917,344
|
$11,849,186 | $0 | 19 Nov 2025 | |
| JANUS HENDERSON GROUP PLC |
13D/G
|
— |
4%
|
1,521,281
|
$9,964,391 | -$3,932,443 | 30 Jun 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
13D/G
|
Company · T. Rowe Price Associates, Inc. |
0.9%
from 13D/G
|
327,423
|
$3,367,000 | — | 31 Dec 2025 | |
| BAKER BROS. ADVISORS LP |
13F
3/4/5
|
Company · 10%+ Owner |
12%
from 3/4/5
|
5,072,730
|
$52,147,664 | — | 31 Dec 2025 | |
| 5AM Venture Management, LLC |
13F
|
Company |
11%
|
4,056,379
|
$41,699,576 | — | 31 Dec 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
5.4%
|
2,088,392
|
$21,468,670 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.3%
|
1,632,460
|
$16,781,689 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.7%
|
1,044,758
|
$10,740,113 | — | 31 Dec 2025 | |
| StepStone Group LP |
13F
|
Company |
2%
|
761,277
|
$7,825,928 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
639,947
|
$6,580,002 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.3%
|
508,789
|
$5,230,351 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.3%
|
497,695
|
$5,116,305 | — | 31 Dec 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.95%
|
362,786
|
$3,729,440 | — | 31 Dec 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.81%
|
310,833
|
$3,193,000 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.76%
|
292,770
|
$3,009,676 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.71%
|
273,378
|
$2,809,666 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.68%
|
260,251
|
$2,675,384 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.66%
|
252,635
|
$2,597,088 | — | 31 Dec 2025 | |
| ROYCE & ASSOCIATES LP |
13F
|
Company |
0.64%
|
247,147
|
$2,540,671 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.59%
|
226,301
|
$2,326,375 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.58%
|
221,269
|
$2,274,645 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.54%
|
205,173
|
$2,109,181 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.47%
|
180,969
|
$1,860,361 | — | 31 Dec 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.46%
|
176,018
|
$1,809,465 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.37%
|
142,110
|
$1,460,891 | — | 31 Dec 2025 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
0.34%
|
128,611
|
$1,322,000 | — | 31 Dec 2025 | |
| Trexquant Investment LP |
13F
|
Company |
0.32%
|
121,280
|
$1,246,758 | — | 31 Dec 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.31%
|
117,668
|
$1,209,627 | — | 31 Dec 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.29%
|
110,942
|
$1,140,484 | — | 31 Dec 2025 | |
| MOORE CAPITAL MANAGEMENT, LP |
13F
|
Company |
0.27%
|
105,000
|
$1,079,400 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.22%
|
85,662
|
$880,606 | — | 31 Dec 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.22%
|
84,893
|
$872,700 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.21%
|
79,375
|
$815,975 | — | 31 Dec 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.2%
|
75,282
|
$773,899 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.18%
|
70,761
|
$727,423 | — | 31 Dec 2025 | |
| Quantinno Capital Management LP |
13F
|
Company |
0.18%
|
67,717
|
$696,131 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.18%
|
67,147
|
$690,272 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.17%
|
66,878
|
$687,506 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.17%
|
65,979
|
$678,263 | — | 31 Dec 2025 | |
| CANTOR FITZGERALD, L. P. |
13F
|
Individual |
0.15%
|
57,000
|
$585,960 | — | 31 Dec 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.15%
|
56,545
|
$572,320 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.15%
|
56,416
|
$579,956 | — | 31 Dec 2025 | |
| Lynx1 Capital Management LP |
13F
|
Company |
0.13%
|
51,689
|
$531,363 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.13%
|
49,302
|
$506,825 | — | 31 Dec 2025 | |
| Nan Fung Group Holdings Ltd |
13F
|
Company |
0.13%
|
49,082
|
$504,563 | — | 31 Dec 2025 | |
| Brevan Howard Capital Management LP |
13F
|
Company |
0.13%
|
47,967
|
$493,101 | — | 31 Dec 2025 | |
| LOS ANGELES CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.12%
|
45,952
|
$317,068 | — | 31 Dec 2025 |
Institutional Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) as of Q1 2026
As of 31 Mar 2026,
Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) was held by
118 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
25,477,255 shares.
The largest 10 holders included
BAKER BROS. ADVISORS LP, 5AM Venture Management, LLC, BlackRock, Inc., TCG Crossover Management, LLC, VANGUARD CAPITAL MANAGEMENT LLC, WELLINGTON MANAGEMENT GROUP LLP, StepStone Group LP, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, and PRICE T ROWE ASSOCIATES INC /MD/.
This page lists
118
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
113
Q1 2026 holders
118
Holder diff
5
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.